The effectiveness of oral hypoglycemic agents in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus. -Multiple comparison, Dapagliflozin, Pioglitazone vs Glimepiride-

Trial Profile

The effectiveness of oral hypoglycemic agents in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus. -Multiple comparison, Dapagliflozin, Pioglitazone vs Glimepiride-

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs Dapagliflozin (Primary) ; Glimepiride (Primary) ; Pioglitazone (Primary)
  • Indications Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Sep 2017 Status changed from recruiting to active, no longer recruiting.
    • 17 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top